NASDAQ:DMAC

Diamedica Therapeutics Stock Insider Trading

etoro logo Buy DMAC
*Your capital is at risk
$5.65
-0.120 (-2.08%)
At Close: Jun 03, 2026

DiaMedica Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 22.08M and sold 0 DMAC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power

(Last 100 transactions)
100.00
Buy 22.08M shares
Sell 0 shares
100% Buy Activity
Weak Positive Correlation

No Significant Signals

No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date Type Person Role Amount
Aug 15, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 8 233
Value: $49.4K
Aug 14, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 70 414
Value: $421.9K
Aug 14, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 70 414
Value: $421.9K
Aug 13, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 293 601
Value: $1.73M
Aug 13, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 293 601
Value: $1.73M
Aug 11, 2025
Buy
Stock Option (right to buy)
A-Award
Krop Julie
Chief Marketing Officer
Officer 450 000
Value: $2.06M
Aug 11, 2025
Buy
Common Stock
J-Other
Krop Julie
Insider
Other 0
Value: $0
Jul 23, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 1 542 857
Value: $5.40M
Jul 23, 2025
Buy
Common Shares
P-Purchase
Von Koch Thomas
10 Percent Owner
10% Owner 2 857 142
Value: $10.00M
Jul 23, 2025
Buy
Voting Common Shares, no par value per share
P-Purchase
Jacinto Richard Ii
10 Percent Owner
10% Owner 400 000
Value: $1.40M
Jul 23, 2025
Buy
Voting Common Shares, no par value per share
P-Purchase
Jacinto Richard Ii
10 Percent Owner
10% Owner 400 000
Value: $1.40M
Jul 23, 2025
Buy
Common Shares
P-Purchase
Von Koch Thomas
10 Percent Owner
10% Owner 2 857 142
Value: $10.00M
Jul 23, 2025
Buy
Common Shares
P-Purchase
Stahlberg Jan
10 Percent Owner
10% Owner 1 542 857
Value: $5.40M
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Wambeke David J.
Chief Business Officer
Officer 250 000
Value: $1.03M
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Semba Charles Pauling
Director
Director 32 162
Value: $132.2K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Pauls Dietrich John
President & CEO
CEO / President 600 000
Value: $2.47M
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Parsons James T.
Director
Director 40 739
Value: $167.4K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Lewis Tanya
Director
Director 32 162
Value: $132.2K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Kuntz Richard
Director
Director 32 162
Value: $132.2K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Kellen Scott
CFO & Secretary
C-Suite Officer 225 000
Value: $924.8K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Giuffre Randall Michael
Director
Director 32 162
Value: $132.2K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Giuffre Randall Michael
Director
Director 32 162
Value: $132.2K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Kellen Scott
CFO & Secretary
C-Suite Officer 225 000
Value: $924.8K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Kuntz Richard
Director
Director 32 162
Value: $132.2K
Jun 01, 2025
Buy
Stock Option (right to buy)
A-Award
Lewis Tanya
Director
Director 32 162
Value: $132.2K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT DIAMEDICA THERAPEUTICS INC.
DiaMedica Therapeutics
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic ...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
3.65% Jun 01
RUN
$12.83
15.74% May 06
GLBE
$31.61
0.569% May 05
SAP
$172.39
4.80% May 05
ADBE
$243.57
5.20% Apr 29

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE